Beclometasone dipropionate with formoterol fumarate dihydrate

PBAC's latest decision on Beclometasone dipropionate with formoterol fumarate dihydrate: Recommended with restriction (2024). Considered for Maintenance and reliever therapy (MART) for asthma in adults (18 years and older) with frequent asthma symptoms despite treatment with inhaled corticosteroids and/or long-acting beta-2 agonists.

Eligible population

Adults (18 years and older) with asthma who have experienced frequent asthma symptoms while receiving treatment with a combination of an inhaled corticosteroid and long-acting beta-2 agonist and require single maintenance and reliever therapy.

Therapy area

Respiratory

Line of therapy

Any

Evidence base

RCT

Primary endpoint

Time to first severe exacerbation

Key trials

CSR-0042, SAKURA, SMILE, STAY, Papi 2013, Patel 2013

Comparator

budesonide 200 µg with formoterol 6 µg (BUD/FOR 200/6)

Economic model

Cost-minimisation

ICER note

Cost-minimisation analysis; no ICER calculated by design.

Submission history

• Jul 2020: Recommended with restriction · Authority Required
• Mar 2022: Recommended with restriction · Authority Required
• Mar 2024: Recommended with restriction · Authority Required

Similar precedents

• Beclometasone with formoterol
  similarity 0.93
• Beclometasone dipropionate with formoterol fumarate dihydrate and glycopyrronium
  similarity 0.78
• Fluticasone propionate with eformoterol fumarate
  similarity 0.76
• Fluticasone propionate with salmeterol xinafoate
  similarity 0.75
• Beclometasone dipropionate with formoterol fumarate dihydrate and glycopyrronium bromide
  similarity 0.74
• Fluticasone propionate with salmeterol
  similarity 0.74